Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
|Articles|November 2, 2016
- Pharmaceutical Technology-11-02-2016
- Volume 40
- Issue 11
Biomolecule Separator Reduces Sample Absorption
Yarra 1.8µm SEC-X300 from Phenomenex is a high-resolution gel filtration chromatography (GFC)/aqueous size-exclusion chromatography (SEC) column for the separation of high molecular weight biomolecules on high-performance liquid chromatography and ultra-high pressure liquid chromatography systems.
Yarra 1.8µm SEC-X300 from Phenomenex is a high-resolution gel filtration chromatography (GFC)/aqueous size-exclusion chromatography (SEC) column for the separation of high molecular weight biomolecules on high-performance liquid chromatography and ultra-high pressure liquid chromatography systems. With a separation range of 10K to 700KDa and high efficiency, SEC-X300 is ideal for separating and characterizing monoclonal antibody aggregates, antibody drug conjugates, and biosimilars in drug discovery and development research. Yarra SEC-X150 and -X300 columns typically operate at backpressures below 3500 psi. The proprietary Yarra surface chemistry, combined with bio-inert column hardware, reduce sample adsorption.
Articles in this issue
about 10 years ago
The Human Factor in Inspectionsabout 10 years ago
Application of QbD and QRM to Analytical Method Validationabout 10 years ago
Biosimilars to Drive Modern Manufacturing Approachesabout 10 years ago
Cleaning Validation in Continuous Manufacturingabout 10 years ago
Lubrication in Continuous Tubular Powder Blendersabout 10 years ago
Integrated Membrane for Single-Use Filtration Assembliesabout 10 years ago
Dual-Shaft Mixers Provide Efficient Turnoverabout 10 years ago
Workstations Allow for Continuous Control of Cell Culture Processesabout 10 years ago
Dissolution TestingRelated to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
3
Our Biggest Takeaways From AAPS PharmSci 360
4
Pimicotinib TGCT Approval Shows How Assessment Aid Supports Review
5